75 Results for "

Nav1.7 channels

" in MedChemExpress (MCE) Product Catalog:
Products (75)

75 Results for "Nav1.7 channels" in MCE Product Catalog:

5
5 Cited Publications
Cat. No.: HY-N0212
CAS No.: 23496-41-5
Synonyms: Verticine; Dihydroisoimperialine
Peimine (Verticine; Dihydroisoimperialine) is an orally active natural product. Peimine has anti-inflammatory, analgesic and cough relieving effects. Peimine can be used in cancer and inflammation related research .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N6691
CAS No.: 71-62-5
Synonyms: 3-Veratroylveracevine
Veratridine (3-Veratroylveracevine) is a plant neurotoxin, a voltage-gated sodium channels (VGSCs) agonist. Veratridine inhibits the peak current of Nav1.7, with an IC50 of 18.39 µM. Veratridine regulates sodium ion channels mainly by activating sodium ion channels, preventing channel inactivation and increasing sodium ion flow .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P10234A
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Poneratoxin acetate is the acetate salt form of Poneratoxin (HY-P10234). Poneratoxin acetate is the modulator for voltage-gated sodium channel (NaV, EC50 for NaV1.6 and NaV1.7 is 97 nM and 2.3 µM), that lowers the voltage threshold for activation and inhibits the inactivation of channels, enhances the excitability of neurons, and leads to the transmission of pain signals .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-105285
CAS No.: 946846-83-9
Purity:  99.54%
Synonyms: Neu-P11
Piromelatine (Neu-P11) is a melatonin MT1/MT2 receptor agonist, serotonin 5-HT1A/5-HT1D agonist, and serotonin 5-HT2B antagonist. Piromelatine (Neu-P11) possesses sleep promoting, analgesic, anti-neurodegenerative, anxiolytic and antidepressant potentials. Piromelatine (Neu-P11) also possesses pain-related P2X3, TRPV1, and Nav1.7 channel-inhibition capacities .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12811
CAS No.: 1235397-05-3
Purity:  99.29%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

PF-04856264 is a potent and selective Nav1.7 inhibitor, with IC50s of 28, 131, 19, and 42 nM for human, mouse, cynomolgus monkey and dog Nav1.7, respectively. PF-04856264 has low potency against the rat Nav1.7 channel. PF-04856264 shows analgesic effect .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-A0079
CAS No.: 94-24-6
Synonyms: Amethocaine
Research Areas:  

Neurological Disease

Tetracaine (Amethocaine) is a sodium channel inhibitor and ryanodine receptor (RyR) inhibitor. Tetracaine blocks sodium conduction across nerve cell membranes, preventing rapid sodium ion influx and depolarization. Tetracaine exhibits biphasic effects on spontaneous sarcoplasmic reticulum Ca 2+ release in Ca 2+-overloaded ventricular myocytes, and increases sarcoplasmic reticulum Ca 2+ load. Tetracaine can be used in research related to eye diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-133910
CAS No.: 849000-18-6
Purity:  98.02%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Lu AE98134, an activator of voltage-gated sodium channels, acts as a partly selective Nav1.1 channels positive modulator. Lu AE98134 also increases the activity of Nav1.2 and Nav1.5 channels but not of Nav1.4, Nav1.6 and Nav1.7 channels. Lu AE98134 can be used to analyze pathophysiological functions of the Nav1.1 channel in various central nervous system diseases, including cognitive restoring in schizophrenia, et al .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-100727
CAS No.: 1443373-17-8
Purity:  98.06%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel Nav1.7 with an IC50 of 0.16 μM for human Nav1.7.
loading...
    loading...
Cat. No.: HY-125079
CAS No.: 1233231-30-5
Purity:  98.33%
Synonyms: ANP-230
DSP-2230 is the orally active inhibitor for voltage-gated sodium channel that inhibits Nav1.7-, Nav1.8-, and Nav1.9-derived sodium currents with IC50s of 7.1 μM, 11.4 μM and 6.7 μM, respectively. DSP-2230 can be used to improve neuropathic pain .
loading...
    loading...
Cat. No.: HY-12796
CAS No.: 934240-30-9
Purity:  99.85%
Synonyms: Vixotrigine; GSK-1014802; CNV1014802
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Raxatrigine (GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.
loading...
    loading...
Cat. No.: HY-12796A
CAS No.: 934240-31-0
Purity:  98.94%
Synonyms: Vixotrigine hydrochloride; GSK-1014802 hydrochloride; CNV1014802 hydrochloride
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Raxatrigine hydrochloride (GSK-1014802 hydrochloride) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.
loading...
    loading...
Cat. No.: HY-118952A
CAS No.: 1834610-75-1
Purity:  99.38%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

PF-06456384 trihydrochloride is an extremely potent and selective Nav1.7 sodium channel blocker (IC50: 0.01 nM for hNaV1.7; 75 nM for rNaV1.7; <0.1 nM for mNaV1.7). PF-06456384 trihydrochloride shows no significant analgesic efficacy in the mouse Formalin pain model .
loading...
    loading...
Cat. No.: HY-16723
CAS No.: 1259933-16-8
Synonyms: TV 45070; XEN402
Funapide (TV 45070; XEN402) is an orally active inhibitor of voltage-gated sodium channels (VGSC) in the peripheral nervous system with IC50 values ??of 84 nM and 54 nM for Nav1.5 and Nav1.7, respectively. Funapide has analgesic effects .
loading...
    loading...
Cat. No.: HY-112279
CAS No.: 1629063-81-5
Purity:  98.15%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

GNE-131 is a potent and selective inhibitor of human sodium channel NaV1.7, with an IC50 of 3 nM.
loading...
    loading...
Cat. No.: HY-107405
CAS No.: 1211866-85-1
Purity:  99.67%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

TC-N 1752 is a potent and orally active inhibitor of Nav1.7, with IC50s of 0.17 μM, 0.3 μM, 0.4 μM, 1.1 μM and 2.2 μM at hNav1.7, hNav1.3, hNav1.4, hNaV1.5 and rNav1.8, respectively. TC-N 1752 also inhibits tetrodotoxin-sensitive sodium channels. TC-N 1752 shows analgesic efficacy in the Formalin model of pain .
loading...
    loading...
Cat. No.: HY-N1847
CAS No.: 21913-98-4
3'-Methoxydaidzein is a isoflavone and a Sodium Channel inhibitor. 3'-Methoxydaidzein inhibits subtypes NaV1.7, NaV1.8 and NaV1.3 with IC50 of 181 nM, 397 nM, and 505 nM, respectively. 3'-Methoxydaidzein exerts analgesic activity by inhibiting voltage-gated sodium channels .
loading...
    loading...
Cat. No.: HY-122001
CAS No.: 1235406-03-7
Purity:  99.69%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

PF-05186462 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channel, with an IC50 of 21 nM. PF-05186462 shows significant selectivity for Nav1.7 versus other sodium channels (Nav 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, and 1.8). PF-05186462 can be used for the research of acute or chronic pain .
loading...
    loading...
Cat. No.: HY-P1221A
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

ProTx II TFA is a selective blocker of Nav1.7 sodium channels, with an IC50 value of 0.3 nM and a Ki of 0.389 nM against human NaV1.7. ProTx II TFA selectively blocks spinal cord NaV1.7 by reducing conductance and altering voltage dependence of activation, preferentially binds to the splice region of aNaV1.5, and can also block sodium channel subtypes such as Nav1.4 and Nav1.6. ProTx II TFA alleviates thermal hyperalgesia in diabetic mice and prevents the propagation of action potentials in nociceptors. ProTx II TFA can be used for research related to painful diabetic neuropathy and pain disorders .
loading...
    loading...
Cat. No.: HY-157802
CAS No.: 2834106-06-6
Purity:  99.35%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

LTGO-33 is a potent and selective voltage-gated sodium channel NaV1.8 inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human DRG neurons, where it reduces action potential firing. LTGO-33 can be used for pain disorders research .
loading...
    loading...
Cat. No.: HY-101789
CAS No.: 1788872-06-9
Purity:  98.21%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Nav1.7-IN-3 is a selective, orally bioavailable voltage-gated sodium channel Nav1.7 inhibitor with an IC50 of 8 nM. Pain relief. Limited CNS penetration .
loading...
    loading...